SLC5A2 and cardiovascular disorder: We also included the newest developments in kidney research by including the cardio- and kidney protective effect of SGLT2 inhibitors in addition to RAS inhibition, and by adding albuminuria and eGFR to the SCORE2 algorithm to improve cardiovascular disease risk prediction.30